IGF::OT::IGF - PAUL C. ANDERSON MEDICINAL CHEMISTRY CONSULTANT SUPPORT SERVICES

IGF::OT::IGF - PAUL C. ANDERSON 药物化学顾问支持服务

基本信息

批准号：
10565656
负责人：
PAUL C ANDERSON
金额：
$ 1.8万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-02-28 至 2023-02-27
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10565656
关键词：
Address Area Biological Biological Assay Biology Chemical Structure Chemistry Chronic Clinical Research Clinical Trials Consult Contractor Contracts Data Development Development Plans Disease Drug Industry Drug Modelings Electronic Mail Feedback Funding Helping to End Addiction Long-term Hour Individual Industry Institutes Investigational Drugs Knee Osteoarthritis Lead Methodology Neurosciences Neurosciences Research Opiate Addiction Pain Pain management Perioperative Pharmaceutical Chemistry Pharmaceutical Preparations Preparation Principal Investigator Process Quality of life Reporting Research Research Contracts Research Personnel Role Seasons Services Speed Strategic Planning Teleconferences Telephone Testing Therapeutic Time United States National Institutes of Health Visit Work chronic musculoskeletal pain clinical pain design drug development drug discovery improved indexing innovation lead optimization meetings member nervous system disorder novel preclinical safety programs symposium virtual

项目摘要

The NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT). This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.

NIH的神经科学研究蓝图代表16个NIH机构和中心，宣布了神经疗法的挑战，以解决有效的药物来应对这一巨大挑战的有效药物。发展和企业的发展专业知识是用什一堂的tilogy tilogy of the Eseach的力量。调查人员具有引人注目的治疗方法与高级级别的生物活性分析和生物学工作相匹配，并签约研究组织（CROS）实施所有其他开发活动。一个项目将构成领先的开发团队（LDT）。这项研究是NIH的长期（治愈）计划，以加快科学解决方案，以了解疼痛的基础，并且是临床疼痛管理的一部分。依赖性。